Logo
x

Search category

Subscribe Now

Ipsen

Ipsen’s Sohonos (palovarotene) Receives the US FDA’s Approval for Fibrodysplasia Ossificans Progressiva

Ipsen’s Sohonos (palovarotene) Receives the US FDA’s Approval for Fibrodysplasia Ossificans Progressiva

  • August 16, 2023
Ipsen’s Bylvay (odevixibat) Receives the US FDA’s Approval for the Treatment of Cholestatic Pruritus Due to Alagille Syndrome

Ipsen’s Bylvay (odevixibat) Receives the US FDA’s Approval for the Treatment of Cholestatic Pruritus Due to Alagille Syndrome

  • June 14, 2023
PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

  • April 3, 2023
Ipsen Presents P-III Trial (NAPOLI 3) Results of Onivyde for Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI 2023

Ipsen Presents P-III Trial (NAPOLI 3) Results of Onivyde for Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI 2023

  • January 23, 2023
Ipsen to Acquire Albireo for ~$952M

Ipsen to Acquire Albireo for ~$952M

  • January 10, 2023
Ipsen Reports P-III (NAPOLI 3) Trial Results of Onivyde for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Reports P-III (NAPOLI 3) Trial Results of Onivyde for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

  • November 9, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.